• 1.

    Floege J, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:268280.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Rovin BH, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:281295.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Goodship TH, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2017; 91:539551.

    • Crossref
    • Search Google Scholar
    • Export Citation

KDIGO Quo Vadis: Updating Guidance for the Management and Treatment of Glomerulonephritis

  • 1 Jürgen Floege, MD, PhD, is director of the Division of Nephrology, Rheinisch-Westfälische Technische Hochschule Aachen University, Aachen, Germany. Brad H. Rovin, MD, is director of the Division of Nephrology, Wexner Medical Center at Ohio State University, Columbus, USA.
Restricted access

In November 2017, KDIGO hosted a Controversies Conference in Singapore on glomerular diseases. The goal was to determine the best practice and evidence gaps in the treatment of glomerular diseases, review the key literature published since the 2012 KDIGO Glomerulonephritis (GN) Guideline, identify topics or issues for future guideline updating, and outline unmet needs in the management of GN (1, 2).

Since the 2012 KDIGO GN guideline, there have been marked advances in our understanding of the pathogenesis, diagnosis, and potential new treatment approaches or therapeutic agents for several glomerular diseases. A few highlights follow.

IgA

Save